Treatment Options After Progression on Frontline Maintenance Therapy
May 13th 2022Petros Grivas, MD, PhD, revisits the patient profile and invites panel members to share recommended treatment options for patients with or without FGFR mutations, who progress after chemotherapy and maintenance avelumab.